GlyNAC: Glycine + NAC for Glutathione Restoration in Aging — What the Baylor Trials Show

GlyNAC is the combination of glycine and N-acetylcysteine (NAC), supplied as the two precursor amino acids for glutathione synthesis. Glutathione (GSH) is the body's most abundant intracellular antioxidant; tissue concentrations decline with age, and that decline correlates with mitochondrial dysfunction, insulin resistance, and inflammation. The supplement's recent attention rests on a small but striking series of trials from Baylor College of Medicine showing that GlyNAC supplementation restores tissue glutathione and improves multiple ageing markers.

Why glycine and cysteine together

Glutathione is a tripeptide of glutamate, cysteine, and glycine. Cysteine is the rate-limiting amino acid for synthesis under most conditions, which is why NAC alone has been used clinically for decades (acetaminophen overdose, mucolysis, COPD) [1]. The Baylor group argued that older adults are deficient in both glycine and cysteine — and that supplying NAC alone fails to restore tissue GSH because glycine becomes limiting [2]. This is the core innovation: pair the two.

What the published trials show

An open-label pilot in eight older adults gave GlyNAC (1.33 mmol/kg/day glycine + 0.81 mmol/kg/day NAC) for 24 weeks. Erythrocyte glutathione concentrations rose, mitochondrial dysfunction markers improved, and grip strength, gait speed, and cognitive measures showed modest improvement [3]. A subsequent 16-week randomised placebo-controlled trial in 24 older adults reported similar findings, with significant improvements in body composition and exercise capacity [4]. A trial in HIV patients (a population with accelerated aging features) reported similar restoration of GSH and improvements in oxidative stress markers [5].

What's still missing

All trials so far come primarily from one research group, are small (n<25), and are short (≤24 weeks). No multi-centre, large-scale randomised trial has confirmed the findings. Hard endpoints — incident frailty, cardiovascular events, mortality — have not been studied. Long-term safety data beyond a few months do not exist.

Safety profile

NAC at gram-level doses can cause GI upset, headache, and rare allergic reactions; rare hepatotoxicity has been reported with very high doses. Glycine is generally well tolerated up to several grams daily. The most important safety considerations are drug interactions (NAC may potentiate vasodilator effects of nitrates, may interact with anticoagulants), and theoretical concerns in cancer settings — high antioxidant levels can in principle protect tumour cells from oxidative therapy [6].

Dosing in the published trials

The Baylor protocol uses ~100 mg/kg/day of glycine and ~100 mg/kg/day of NAC — for a 70 kg adult, roughly 7 g of each daily, divided. That is far higher than typical over-the-counter NAC doses (600–1,200 mg/day) and most "GlyNAC" supplement products contain much less than the trial dose [7]. Whether lower doses produce meaningful GSH restoration is unproven.

Practical takeaway

GlyNAC is one of the most interesting "geroscience" interventions in early human trials, with biological plausibility and consistent — if small — clinical signals. The published doses are high (around 7 g + 7 g daily) and short-term safety has been acceptable. It is not a substitute for exercise, sleep, or dietary protein adequacy. People considering it should review medications (especially nitrates and anticoagulants), avoid it during active cancer therapy without oncology input, and recognise that long-term outcome data remain to be generated.

Why this might matter for specific patient populations

Beyond healthy ageing, glutathione deficiency is documented in HIV, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, type 2 diabetes, and Parkinson's disease. NAC alone has been used in several of these settings with mixed results. The GlyNAC hypothesis — that combined supplementation overcomes the glycine bottleneck — could explain some of the prior trial inconsistency. Larger, multi-centre trials in COPD and idiopathic pulmonary fibrosis are now underway and should clarify whether the combination outperforms NAC alone.

Practical implementation if a clinician supports a trial

Spreading the dose across three or four servings daily is more tolerable than one or two large doses; mixing with cold water and a small amount of acid (lemon, juice) can mask NAC's sulphur taste. Some people prefer effervescent NAC products; others use glycine separately because it is sweet and pleasant on its own. Take with food to reduce nausea. Periodic monitoring of liver function and a basic metabolic panel during the first three months is sensible given the dose magnitude and limited long-term safety data.